Trials / Completed
CompletedNCT00276380
A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
A Phase III, Multicentre, Randomised, Double-blinded, Parallel Group, Placebo Controlled Clinical Study for Evaluating the Efficacy of EGb 761® (Tanakan®) (240mg) in the Recovery of Neurological Impairment Following Ischemic Stroke
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 204 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGb761 | EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months. |
| DRUG | Placebo | Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months. |
| DRUG | Acetylsalicylic acid | Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months. |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2006-01-13
- Last updated
- 2019-01-08
- Results posted
- 2018-02-19
Locations
10 sites across 4 countries: Czechia, Poland, Romania, Russia
Source: ClinicalTrials.gov record NCT00276380. Inclusion in this directory is not an endorsement.